penpulimab + lenalidomide + rituximab + gemcitabine + oxaliplatin

This is a combination therapy consisting of five different drugs: - **Penpulimab**: A PD-1 blocking antibody that works by binding to PD-1 and blocking its interaction with PD-L1 and PD-L2, decreasing tumor growth. Recently approved by the FDA for non-keratinizing nasopharyngeal carcinoma. - **Lenalidomide**: An immunomodulatory drug commonly used in multiple myeloma and other hematologic malignancies. - **Rituximab**: A CD20-directed monoclonal antibody used in various B-cell malignancies. - **Gemcitabine**: A nucleoside analog used in various solid tumors including pancreatic cancer and nasopharyngeal carcinoma. - **Oxaliplatin**: A platinum-based chemotherapy agent used in colorectal cancer and other gastrointestinal malignancies.